Sanofi, Regeneron and Amgen, locked in a PCSK9 market battle, are touting the cholesterol drugs' benefits for patients with diabetes.

Samsung Bioepis has taken a big step toward approval for a Herceptin biosim in Europe.

New stats show diabetes patients who suffer severe hypoglycemia are twice as likely to die. No wonder pharma's touting related data on next-gen meds.

Novo’s combination med Xultophy, key to its growth strategy, can dampen CV risk factors such as LDL cholesterol, a new analysis showed.

Stop worrying that Roche's Tecentriq might lose its bladder cancer nod. After talks with the FDA, the drugmaker says that threat has passed.

Bristol-Myers' immunotherapy Opdivo cut the risk of a melanoma recurrence by 35% compared with its sister med Yervoy, a new study found.

A one-two punch with Bristol-Myers' Opdivo and Yervoy cut the risk of death by 37% for kidney cancer patients with a poor prognosis.

Merck & Co. and Incyte unveiled closely watched data on a one-two punch with Keytruda and the experimental IDO1 inhibitor epacadostat.